BioStock: Cyxone’s Covid-19 trial with Rabeximod initiated in Europe
Last week, the biotech company Cyxone announced that the first patient has been screened in the phase II trial with their candidate drug Rabeximod in patients suffering from moderate Covid-19. The aim of the treatment is to prevent a more serious progression of the condition and ultimately to save lives. BioStock reached out to COO Malin Berthold for a comment.
Read the full interview with Malin Berthold at biostock.se:
This is a pressrelease from BioStock - Connecting Innovation & Capital. https://www.biostock.se/